~~<i id='CDB8BD2C67'><strike id='CDB8BD2C67'><tt id='CDB8BD2C67'><pre id='CDB8BD2C67'></pre></tt></strike></i>~~

Home» focus» knowledge

knowledge

author：explore 2025-10-04 10:03:12 Page View：8691

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Mark Cuban is blaming the wrong people for high drug costs
Next article： Peter Hotez and the public health issue of online harassment

explore

Novavax promises a turnaround & Lilly roils the obesity market

SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

Hospitals are dialing back on venture capital investing

AlexHogan/STATHospitalsoncedoveheadfirstintoventurecapitalwithsplashyheadlinesandattention-grabbingn

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

WASHINGTON--TheSupremeCourtwillreviewarulingstrikingdownadomesticviolencefederalgunban.

Illumina slashes 2023 revenue projections yet again

AdobeSANDIEGO—Afterstartingofftheyearwithlowerrevenueprojectionsthanmarketanalystshadhopedfor,SanDie